EHA 2019: MabCute Study Fails to Uncover Benefit of Extended Rituximab Maintenance in Indolent Non-Hodgkin Lymphoma
Study was underpowered because all patients fared better than expected
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.